Scilex Holding Company Logo

Scilex Holding Company

SCLXW

(1.2)
Stock Price

0,30 USD

-375.19% ROA

145.59% ROE

-2.12x PER

Market Cap.

265.329.452,00 USD

-77.05% DER

0% Yield

-244.59% NPM

Scilex Holding Company Stock Analysis

Scilex Holding Company Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Scilex Holding Company Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (138.97%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 Revenue Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROA

The stock's ROA (-92.8%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (14.65x) suggests it's overvalued, potentially making it an expensive investment.

6 DER

The stock is burdened with a heavy load of debt (362%), making it financially unstable and potentially risky for investors.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-1), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Scilex Holding Company Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Scilex Holding Company Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Scilex Holding Company Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Scilex Holding Company Revenue
Year Revenue Growth
2019 21.033.000
2020 23.560.000 10.73%
2021 31.317.000 24.77%
2022 38.034.000 17.66%
2023 40.468.000 6.01%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Scilex Holding Company Research and Development Expenses
Year Research and Development Expenses Growth
2019 85.517.000
2020 9.961.000 -758.52%
2021 9.201.000 -8.26%
2022 9.054.000 -1.62%
2023 16.288.000 44.41%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Scilex Holding Company General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 0
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Scilex Holding Company EBITDA
Year EBITDA Growth
2019 -134.485.000
2020 -31.481.000 -327.19%
2021 -32.059.000 1.8%
2022 -46.673.000 31.31%
2023 -152.860.000 69.47%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Scilex Holding Company Gross Profit
Year Gross Profit Growth
2019 15.231.000
2020 21.411.000 28.86%
2021 27.683.000 22.66%
2022 27.237.000 -1.64%
2023 26.900.000 -1.25%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Scilex Holding Company Net Profit
Year Net Profit Growth
2019 -178.594.000
2020 -47.519.000 -275.84%
2021 -88.424.000 46.26%
2022 -23.364.000 -278.46%
2023 -142.116.000 83.56%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Scilex Holding Company Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 -1
2020 0 0%
2021 -1 0%
2022 0 0%
2023 -1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Scilex Holding Company Free Cashflow
Year Free Cashflow Growth
2019 -61.005.000
2020 -31.486.000 -93.75%
2021 -28.664.000 -9.85%
2022 -23.325.000 -22.89%
2023 5.745.000 506.01%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Scilex Holding Company Operating Cashflow
Year Operating Cashflow Growth
2019 -60.421.000
2020 -31.461.000 -92.05%
2021 -28.664.000 -9.76%
2022 -21.258.000 -34.84%
2023 5.900.000 460.31%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Scilex Holding Company Capital Expenditure
Year Capital Expenditure Growth
2019 584.000
2020 25.000 -2236%
2021 0 0%
2022 2.067.000 100%
2023 155.000 -1233.55%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Scilex Holding Company Equity
Year Equity Growth
2020 -141.683.000
2021 -223.876.000 36.71%
2022 36.239.000 717.78%
2023 -162.669.000 122.28%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Scilex Holding Company Assets
Year Assets Growth
2020 81.504.000
2021 77.932.000 -4.58%
2022 86.527.000 9.93%
2023 80.528.000 -7.45%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Scilex Holding Company Liabilities
Year Liabilities Growth
2020 223.187.000
2021 301.808.000 26.05%
2022 50.288.000 -500.16%
2023 243.197.000 79.32%

Scilex Holding Company Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.32
Net Income per Share
-0.79
Price to Earning Ratio
-2.12x
Price To Sales Ratio
5.87x
POCF Ratio
-14.64
PFCF Ratio
-15.87
Price to Book Ratio
-1.44
EV to Sales
8.6
EV Over EBITDA
-3.97
EV to Operating CashFlow
-24.23
EV to FreeCashFlow
-23.26
Earnings Yield
-0.47
FreeCashFlow Yield
-0.06
Market Cap
0,27 Bil.
Enterprise Value
0,39 Bil.
Graham Number
4.56
Graham NetNet
-1.62

Income Statement Metrics

Net Income per Share
-0.79
Income Quality
0.14
ROE
4.22
Return On Assets
-1.13
Return On Capital Employed
0.71
Net Income per EBT
1
EBT Per Ebit
1.08
Ebit per Revenue
-2.26
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.36
Research & Developement to Revenue
0.28
Stock Based Compensation to Revenue
0.27
Gross Profit Margin
0.64
Operating Profit Margin
-2.26
Pretax Profit Margin
-2.45
Net Profit Margin
-2.45

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.11
Free CashFlow per Share
-0.12
Capex to Operating CashFlow
0.04
Capex to Revenue
-0.01
Capex to Depreciation
-0.16
Return on Invested Capital
3.13
Return on Tangible Assets
-3.75
Days Sales Outstanding
132.66
Days Payables Outstanding
758.27
Days of Inventory on Hand
91.8
Receivables Turnover
2.75
Payables Turnover
0.48
Inventory Turnover
3.98
Capex per Share
-0

Balance Sheet

Cash per Share
0,01
Book Value per Share
-1,16
Tangible Book Value per Share
-1.53
Shareholders Equity per Share
-1.16
Interest Debt per Share
0.91
Debt to Equity
-0.77
Debt to Assets
1.56
Net Debt to EBITDA
-1.26
Current Ratio
0.11
Tangible Asset Value
-0,21 Bil.
Net Current Asset Value
-0,22 Bil.
Invested Capital
-0.77
Working Capital
-0,20 Bil.
Intangibles to Total Assets
0.63
Average Receivables
0,02 Bil.
Average Payables
0,02 Bil.
Average Inventory
3526000
Debt to Market Cap
0.47

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Scilex Holding Company Dividends
Year Dividends Growth

Scilex Holding Company Profile

About Scilex Holding Company

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

CEO
Mr. Jaisim Shah
Employee
105
Address
960 San Antonio Road
Palo Alto, 94303

Scilex Holding Company Executives & BODs

Scilex Holding Company Executives & BODs
# Name Age
1 Mr. Jaisim Shah
President, Chief Executive Officer & Director
70
2 Mr. Suresh K. Khemani
Senior Vice President & Chief Commercial Officer
70
3 Mr. Steven F. Lincoln J.D.
General Counsel & Chief Compliance Officer
70
4 Dr. Suketu D. Desai Ph.D.
Chief Technology Officer & Senior Vice President
70
5 Ms. Gigi DeGuzman
Executive Director of Administrative Operations & Head of Human Resources
70
6 Dr. Dmitri V. Lissin M.D.
Senior Vice President & Chief Medical Officer
70
7 Mr. Sumant Rajendran
Executive Director of Marketing
70
8 Mike Ciaffi
National Sales Director
70
9 Mr. Stephen Ma
Senior Vice President, Chief Financial Officer & Corporate Secretary
70
10 Dr. Henry H. Ji Ph.D.
Executive Chairman
70

Scilex Holding Company Competitors